A 2026 narrative review of the IL-5/eosinophil axis in eosinophilic granulomatosis with polyangiitis (EGPA) and the two approved IL-5 pathway inhibitors — mepolizumab and benralizumab — covering their mechanisms, MIRRA and MANDARA trial evidence, real-world data, guideline positioning, and the remaining unmet needs.
The 2025 EULAR update to the Behçet’s syndrome recommendations moves monoclonal TNF-alpha inhibitors (especially infliximab) to first-line induction and maintenance for eye, vascular and parenchymal-CNS disease, displacing cyclophosphamide and the azathioprine-first strategy, and broadens treatment targets to angiographic and endoscopic remission.
Step through a 76-year-old woman’s diagnostic journey — palpable purpura, falling kidney function, a stroke, a new murmur — one finding at a time. Fourteen multiple-choice checkpoints test how you reshape the differential as each piece of data lands.